PresentationsInhibitors of the E3 Ubiquitin Ligase CBL-B Promote Potent T and NK Cell Mediated Anti-Tumor Response By AldenMC Production / September 21, 2022
PresentationsFirst Targeted Protein Degrader for Hematologic Malignancies By AldenMC Production / September 20, 2022
PresentationsExploring NX-5948: A CNS Penetrant Selective Degrader of BTK that Significantly Reduces Inflammation in Mouse Models of Autoimmune Disease By AldenMC Production / July 27, 2022
PresentationsA First-in-Human Phase 1 Trial of NX-5948, an Oral BTK Degrader, in Patients with Relapsed and Refractory B-cell Malignancies By AldenMC Production / June 9, 2022
PresentationsA First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Oral BTK Degrader With Immunomodulatory Activity, in Patients With Relapsed and Refractory B-Cell Malignancies By AldenMC Production / June 9, 2022
PresentationsThe CBL-B Inhibitor, NX-0255, Enhances Human Drug-Enhanced Tumor-Infiltrating Lymphocyte (DeTIL) Expansion and T Cell Function in Full-Scale Runs By AldenMC Production / June 6, 2022
PresentationsA Phase 1 Adoptive Cell Therapy Using Drug-Enhanced, Tumor-Infiltrating Lymphocytes, DeTIL-0255, in Adults With Advanced Malignancies By AldenMC Production / June 6, 2022
PresentationsModeling Limit of Detection for Dominant T Cell Receptor Clones Reveals Comparable Measures Across RNA and DNA Based Sequencing By AldenMC Production / June 6, 2022
PresentationsA Phase 1 Adoptive Cell Therapy Using Drug-Enhanced, Tumor-Infiltrating Lymphocytes, DeTIL-0255, in Adults With Advanced Malignancies By AldenMC Production / June 3, 2022
